Navigation Links
Antibody halts cancer-related wasting condition

BOSTON New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death, according to scientists from Dana-Farber Cancer Institute.

Many strategies have been tried to reverse the condition, which may cause such frailty that patients can't endure potentially life-saving treatments, but none have had great success.

Scientists reporting in the July 13 advanced online edition of Nature, led by Bruce Spiegelman, PhD, demonstrated that in mice bearing lung tumors, their symptoms of cachexia improved or were prevented when given an antibody that blocked the effects of a protein, PTHrP, secreted by the tumor cells. PTHrP stands for parathyroid hormone-related protein, and is known to be released from many types of cancer cells.

The scientists said their findings are the first to explain in detail how PTHrP from tumors switches on a thermogenic (heat-producing) process in fatty tissues, resulting in unhealthy weight loss.

This tumor-derived protein, they found, stimulated "beige" or brown fat cells mixed with stored white fat in the body, causing the white fat to "brown" that is, generate heat and cause weight loss even when the animals were at rest.

The researchers carried out two experiments using mice that developed lung tumors and cachexia. In one, they administered a polyclonal antibody that specifically neutralizes PTHrP and found that it prevented the wasting almost completely, while untreated animals became mildly cachexic.

In a second experiment, the antibody treatment prevented the loss of muscle mass and improved muscle function, while control animals developed severe muscle-wasting.

"You would have expected, based on our first experiments in cell culture, that blocking PTHrP in the mice would reduce browning of the fat," said Spiegelman. "But we were surprised that it also affected the loss of muscle mass, and improved health."

The research suggested that PTHrP alone doesn't directly cause muscle wasting, yet blocking the protein's activity prevents it.

Thus, the role of PTHrP "is definitely not the whole answer" to the riddle of cachexia, noted Spiegelman, but may be a necessary part, while other factors are also involved.

A collaborator on the study, Vickie E. Baracos, PhD, at the University of Alberta in Edmonton, Canada, provided the blood of 47 patients with lung or colon cancer who were cachexic. Serkan Kir, PhD, from the Spiegelman lab and first author on the paper found increased levels of PTHrP in 17 of the patients. Those patients had significantly lower lean body mass and were producing more heat energy at rest than were the other patients in the group.

It may turn out that the PTHrP mechanism is responsible for cachexia in a subset, but not all, cancer patients, Spiegelman suggested. Before trying the anti-PTHrP antibody in human patients, he said, "clinicians would probably first want to find out if the protein is elevated in certain cancers, and determine which patients would be good candidates for a clinical trial."

Barrett Rollins, MD, PhD, Dana-Farber's chief scientific officer, commented that the report from Spiegelman and his colleagues "provides a new roadmap for developing a rational, mechanistically based treatment for this incredibly debilitating condition that occurs in such a large number of our patients. Until now we've had no truly effective way to reverse this horrible complication."

Patients with upper gastrointestinal and pancreatic cancers are the most likely to develop cachexia, and the condition affects about 80 percent of terminal cancer patients. Current strategy is to give appetite stimulants and nutrient supplements, along with medications to counteract some of the molecular pathways believed to underlie the wasting process, but with limited success.


Contact: Teresa Herbert
Dana-Farber Cancer Institute

Related biology news :

1. Clinical trial for rabies monoclonal antibody
2. Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis
3. Flu antibody’s one-handed grab may boost effort toward universal vaccine, new therapies
4. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
5. New monoclonal antibody developed that can target proteins inside cancer cells
6. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
7. KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
8. A single-domain antibody that specifically recognizes amyloid-beta 42 oligomers
9. Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer
10. Newly identified B-cell selection process adds to understanding of antibody diversity
11. Parkinson gene: Nerve growth factor halts mitochondrial degeneration
Post Your Comments:
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , ... November 24, 2015 , ... The United States ... of the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green ... or her work with turfgrass. , Clarke, of Iselin, N.J., is an ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an ... is bound to proteins, copper is also toxic to cells. With a $1.3 ... Institute (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
Breaking Biology Technology: